Kinetics, prognostic and predictive values of <i>ESR1</i> circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor

Abstract

ESR1 circulating mutations are independent risk factors for poor outcome after AI failure, and are frequently detectable before clinical progression. Interventional studies based on ESR1 circulating status are warranted.